Stock GTHX G1 THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Real-time Estimate Cboe BZX
Other stock markets
 20:54:35 26/06/2024 BST 		5-day change 1st Jan Change
2.255 USD +2.50% Intraday chart for G1 Therapeutics, Inc. -11.07% -26.23%
06-25 Needham Lowers Price Target on G1 Therapeutics to $6 From $12, Maintains Buy Rating MT
06-25 HC Wainwright Lowers G1 Therapeutics Price Target to $3 From $9, Maintains Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Midday Decliners
Sector Update: Health Care Stocks Advance Premarket Monday
Top Premarket Decliners
G1 Therapeutics Halts Phase 3 Breast Cancer Drug Trial As Data Disappoints
G1 Therapeutics' breast cancer drug fails in late-stage trial
G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer
G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024
TScan Therapeutics, Inc Announces Board and Committee Changes
G1 Therapeutics, Inc. Announces the Presentation of Mature Phase 2 Clinical Trial Results
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting
Sector Update: Health Care Stocks Lower Premarket Wednesday
G1 Therapeutics Grants Deimos Biosciences License to Market Anti-Radiation Treatment -- Shares Up Pre-Bell
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024
G1 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024
G1 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Top Midday Decliners
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GTHX Stock
  4. News G1 Therapeutics, Inc.
  5. Other languages